Loading
Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.
Pralsetinib is a selective RET inhibitor that blocks the RET kinase in tumours driven by RET fusions or mutations while sparing most other kinases. It is used for RET-fusion metastatic non-small-cell lung cancer, where ARROW reported a response rate of about 72% in treatment-naive patients. It was approved in 2020, with full approval in 2023; the thyroid indications were withdrawn in the US in 2023 after Roche returned rights to Blueprint (now Rigel). It remains an option in RET-fusion NSCLC but is less used than selpercatinib, which has randomised phase 3 support and a broader label. For a newcomer, pralsetinib is the second of two RET-selective pills, effective but overshadowed by commercial and label changes rather than by weak efficacy.
Selective RET inhibitor. Connects to RET.
1.Pralsetinib slips into a pocket on RET.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA812. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 5.8 years later, when the FDA's table was read.
Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
Withdrawn: the indication came off the label 2.6 years after its accelerated approval.
Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
Confirmed: the accelerated approval of 2020 converted to traditional approval 2.9 years after it was granted.
| Region | Year | Indication |
|---|---|---|
| US | 2020 | RET-fusion metastatic NSCLC (full approval 2023) |
| England (NICE) | 2022 | RET fusion-positive advanced non-small-cell lung cancer in patients who have not had a RET inhibitor: not recommended · TA812, published 3 August 2022, does not recommend pralsetinib within its marketing authorisation, so it is not routinely funded in England. |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pralsetinib" OR ABSTRACT:"Pralsetinib" OR TITLE:"Gavreto" OR ABSTRACT:"Gavreto") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pralsetinib, not a curated reading list.
Shares ARROW (thyroid cohorts), Medullary thyroid cancer, Selpercatinib, RET fusion-positive non-small-cell lung cancer.
Shares ARROW (thyroid cohorts), Selpercatinib, RET fusion-positive non-small-cell lung cancer, RET.
Shares Thyroid cancer (KEGG map), Medullary thyroid cancer, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), RET.
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer, RET, Thyroid cancer.
Shares Medullary thyroid cancer, Selpercatinib, Thyroid cancer, Small-molecule kinase inhibitors.
Shares Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), Selpercatinib, RET, Thyroid cancer.
Shares Medullary thyroid cancer, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), Selpercatinib, RET.
Shares Selpercatinib, RET, Thyroid cancer, Small-molecule kinase inhibitors.